Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
XORTX Therapeutics Inc ( (TSE:XRTX) ) just unveiled an announcement.
On May 15, 2025, XORTX Therapeutics Inc. released its condensed interim consolidated financial statements for the three months ended March 31, 2025. The company reported a net loss of $698,673 for the period, an improvement from the $3,018,936 loss in the same period in 2024. The financial results highlight increased research and development expenses, reflecting the company’s ongoing commitment to advancing its therapeutic programs. The report also noted a decrease in total assets and shareholders’ equity compared to the previous quarter, indicating financial challenges that may impact future operations and stakeholder interests.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a company operating in the biotechnology industry, focusing on developing therapies for the treatment of progressive kidney disease and other health conditions related to excess uric acid. The company is primarily engaged in research and development activities to bring innovative solutions to the market.
Average Trading Volume: 6,040
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$5.11M
See more data about XRTX stock on TipRanks’ Stock Analysis page.